dementia

shutterstock_189857270

Introduction

Dementia is a syndrome resulting from brain disease, characterised by a global cognitive decline, which may include disturbances of thinking, memory, comprehension and orientation.

Symptoms can vary, depending on the cause, but memory difficulties are often the first problem to be noticed. There is sometimes a change in personality with alterations in behaviour, termed ‘BPSD’ (behavioural and psychological symptoms of dementia).

There are several types of dementia. We could talk about each in much greater detail, but in summary the most prevalent types are:

  • Alzheimer’s disease (most common form of dementia)
  • Lewy body dementia
  • Vascular dementia
  • Frontotemporal dementia
  • Rarer causes e.g. HIV, vitamin B12 deficiency, etc

What we already know

Screening and diagnosis of dementia has much improved over the last few years, with many areas of the country having a specific ‘memory clinic’ service, although controversy remains about which instrument to use to diagnose dementia.

The management of dementia includes both pharmacological treatment and non-pharmacological considerations (e.g. ensuring the environment is appropriate, providing activity and stimulation and addressing communication needs).

The use of acetylcholinesterase inhibitors has become much more widespread over recent years and, although it is no wonder drug or cure, for some people with Alzheimer’s, it can slow the progression of the disease. NICE guidelines recommend the use of Donepezil, Galantamine or Rivastigmine for mild-moderate Alzheimer’s disease. Mematine is recommended as an option for those with moderate Alzheimer’s disease who cannot tolerate acetylcholinesterase inhibitors, or for those with severe Alzheimer’s disease.

Areas of uncertainty

What actually causes dementia? We know lots of factors and even some genetic changes that are associated with dementia but we know little about the actual direct causes of dementia.

There is also uncertainty about the reason that some people progress from Mild Cognitive Impairment (memory impairment that does not meet diagnostic threshold of dementia) to dementia and how to predict who this will happen to.

What’s in the pipeline

Media reports often hint at a progression towards finding a cure for dementia. In practice we may not be that close, but there are several areas that researchers are working on:

  • Gene therapy
  • A vaccine for dementia
  • The use of stem cells to develop replacement cells lost in dementia

References

Giebel, C. M., Sutcliffe, C., Stolt, M., Karlsson, S., Renom-Guiteras, A., Soto, M., … Challis, D. (2014). Deterioration of basic activities of daily living and their impact on quality of life across different cognitive stages of dementia: a European study. International Psychogeriatrics / IPA, 26(8), 1283–93. doi:10.1017/S1041610214000775 [Abstract]

NICE guidelines CG42 (2015) “Dementia: Supporting people with dementia and their carers in health and social care” [PDF]

Semple, D. and Smyth, R. (eds.) (2013) Oxford Handbook of Psychiatry. 3rd ed. Oxford: Oxford University Press. [Publisher]

Acknowledgement

Written by: Josephine Neale
Reviewed by:
Last updated: Sep 2015
Review due: Sep 2016

Our dementia Blogs

First national bereavement survey published by the Department of Health

shutterstock_101717590

The Department of Health have published the results of the first nationwide survey of bereaved relatives in England. The survey looked at the last 3 months of life and assessed the quality of care that people received and how this varied in different parts of the country and in different groups of patients. The postal [read the full story…]

End of life care for people with dementia: new research briefing from SCIE

shutterstock_90826127

End of life care is an emotive subject and perhaps none more so than in people with dementia where it can be particularly difficult to ensure that individuals get the care they want in the final months of their life. Both the Department of Health and NICE have published guidance in this area and this [read the full story…]

Omega-3 fish oil supplements don’t help with cognitive decline or dementia in the short-term, according to new Cochrane review

shutterstock_55385059

Fish oil supplements are big business. The worldwide omega-3 market has recently been valued at around $5 billion with 40% growth predicted between 2010 and 2015. Omega-3 fatty acids are fats responsible for many important jobs in the body. We get these fats through our daily diets and the three major omega-3 fats are: Alpha [read the full story…]

Memory clinics no better than GP care for post-diagnosis treatment of dementia, according to new RCT

shutterstock_1164532

Memory clinics are becoming more widespread in the UK and elsewhere. They offer assessment, support, information and advice to people with memory problems and their carers. GPs will often refer patients to memory clinics if they feel that they may be in the early stages of dementia, but need an assessment before a diagnosis can [read the full story…]

New CQUIN guidance focuses on identifying and referring people with dementia

shutterstock_89803582

The Commissioning for Quality and Innovation (CQUIN) payment framework enables commissioners to reward excellence by linking a proportion of providers’ income to the achievement of local quality improvement goals. The framework aims to embed quality within commissioner-provider discussions and to create a culture of continuous quality improvement, with stretching goals agreed in contracts on an [read the full story…]

Cholinesterase inhibitors are an effective treatment for patients with Parkinson’s disease with dementia

shutterstock_95211772

People with Alzheimer’s disease experience a loss of nerve cells that use a chemical called acetylcholine as a chemical messenger. Dementia symptoms become more severe as more nerve cells are lost. Cholinesterase inhibitors are a group of drugs (including donepezil, rivastigmine and galantamine) that prevent the enzyme acetylcholinesterase from breaking down acetylcholine in the brain. [read the full story…]

Comparative risks of antipsychotics amongst nursing home residents with dementia

shutterstock_72596107

Regular readers may recall previous blogs where I have written about the dangers associated with antipsychotic drugs in elderly patients. Many of you have responded simply and emotionally on Twitter by saying: “Stop prescribing these drugs!” Others have recognised that the issue is far from clear cut as a fair proportion of patients do have [read the full story…]

Functional analysis may be a promising alternative treatment for challenging behaviour in dementia

shutterstock_64903231

Mood, memory and behaviour are all affected by dementia and it is not unusual for behaviour to become ‘challenging’. People with dementia may become agitated or aggressive and this can be extremely difficult and stressful for family members and carers. Challenging behaviour has traditionally been managed with antipsychotic drugs, despite the fact that they do [read the full story…]

When is it appropriate to prescribe antipsychotics to treat the behavioural and psychological symptoms of dementia?

shutterstock_11551324

This topic has been well publicised in recent years and for good reason. We know that there is a huge disparity between the number of people with dementia who are prescribed antipsychotics (180,000 in England each year) and the number who may derive some benefit from the treatment (36,000). We also know that dangerous side [read the full story…]

No evidence for the use of aspirin, steroids or NSAIDs for the treatment of Alzheimer’s disease

shutterstock_16791472

Alzheimer’s disease affects 1-2% of people aged 65-70 and approximately 20% of those over 80 years. As our population ages, the condition is on the increase and it’s estimated that 2030, an estimated 7.7 million Americans aged 65 and older will have Alzheimer’s disease. We do not yet know exactly how and why Alzheimer’s disease [read the full story…]